Paul C - Search Results

1

Comparison of the intracellular pharmacokinetics of daunorubicin and idarubicin in patients with acute leukemia.

Tidefelt U, Sundman-Engberg B, Paul C. Tidefelt U, et al. Among authors: paul c. Leuk Res. 1994 Apr;18(4):293-7. doi: 10.1016/0145-2126(94)90032-9. Leuk Res. 1994. PMID: 8170171

2

A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia.

Gruber A, Björkholm M, Brinch L, Evensen S, Gustavsson B, Hedenus M, Juliusson G, Löfvenberg E, Nesthus I, Simonsson B, Sjo M, Stenke L, Tangen JM, Tidefelt U, Udén AM, Paul C, Liliemark J. Gruber A, et al. Among authors: paul c. Leuk Res. 2003 Apr;27(4):323-8. doi: 10.1016/s0145-2126(02)00181-9. Leuk Res. 2003. PMID: 12531223 Clinical Trial.

3

In vitro chemosensitivity testing of selected myeloid cells in acute myeloid leukemia.

Möllgård L, Prenkert M, Smolowicz A, Paul C, Tidefelt U. Möllgård L, et al. Among authors: paul c. Leuk Lymphoma. 2003 May;44(5):783-9. doi: 10.1080/1042819031000067594. Leuk Lymphoma. 2003. PMID: 12802914

4

Higher plasma but not intracellular concentrations after infusion with liposomal daunorubicin compared with conventional daunorubicin in adult acute myeloid leukemia.

Löfgren C, Lehmann S, Jönsson-Videsäter K, Möllgård L, Linder O, Tidefelt U, Hassan M, Paul C. Löfgren C, et al. Among authors: paul c. Ther Drug Monit. 2007 Oct;29(5):626-31. doi: 10.1097/FTD.0b013e318156e938. Ther Drug Monit. 2007. PMID: 17898654

5

DNA as a carrier for anthracyclines in the treatment of acute myelocytic leukemia (AML).

Gahrton G, Tidefelt U, Paul C, Björkholm M, Grimfors G, Hast R, Juliusson G, Järnmark M, Killander A, Kimby E, et al. Gahrton G, et al. Among authors: paul c. Leukemia. 1992;6 Suppl 2:89-91. Leukemia. 1992. PMID: 1578953 Clinical Trial. No abstract available.

6

Expression of glutathione transferase pi as a predictor for treatment results at different stages of acute nonlymphoblastic leukemia.

Tidefelt U, Elmhorn-Rosenborg A, Paul C, Hao XY, Mannervik B, Eriksson LC. Tidefelt U, et al. Among authors: paul c. Cancer Res. 1992 Jun 15;52(12):3281-5. Cancer Res. 1992. PMID: 1596886

7

The cytotoxic effects of 5-OH-1,4-naphthoquinone and 5,8-diOH-1,4-naphthoquinone on doxorubicin-resistant human leukemia cells (HL-60).

Segura-Aguilar J, Jönsson K, Tidefelt U, Paul C. Segura-Aguilar J, et al. Among authors: paul c. Leuk Res. 1992 Jun-Jul;16(6-7):631-7. doi: 10.1016/0145-2126(92)90013-w. Leuk Res. 1992. PMID: 1635381

8

Intracellular uptake and cytotoxic effect in vitro of doxorubicin and epirubicin in human leukemic and normal hematopoietic cells.

Tidefelt U, Sundman-Engberg B, Paul C. Tidefelt U, et al. Among authors: paul c. Cancer Chemother Pharmacol. 1991;29(1):7-12. doi: 10.1007/BF00686328. Cancer Chemother Pharmacol. 1991. PMID: 1742852

9

Intracellular concentrations of anti cancer drugs in leukemic cells in vitro vs in vivo.

Sundman-Engberg B, Tidefelt U, Liliemark J, Paul C. Sundman-Engberg B, et al. Among authors: paul c. Cancer Chemother Pharmacol. 1990;25(4):252-6. doi: 10.1007/BF00684881. Cancer Chemother Pharmacol. 1990. PMID: 2295112

10

In vitro drug testing in patients with acute leukemia with incubations mimicking in vivo intracellular drug concentrations.

Tidefelt U, Sundman-Engberg B, Rhedin AS, Paul C. Tidefelt U, et al. Among authors: paul c. Eur J Haematol. 1989 Nov;43(5):374-84. doi: 10.1111/j.1600-0609.1989.tb00323.x. Eur J Haematol. 1989. PMID: 2482193 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,187 results

Search Page

Filters